[Broomfield, CO] – February 20, 2025 – VSi Parylene, a leading provider of high-quality parylene coating services for the medical device industry, today announced its acquisition by Integer Holdings Corporation. This strategic move marks a significant milestone in VSi Parylene’s growth and reinforces its commitment to delivering exceptional coating solutions to its global clientele.
Since its inception, VSi Parylene has established itself as a trusted partner for medical device manufacturers seeking reliable and precise parylene coating applications. The company’s expertise in applying ultra-thin, biocompatible coatings has been instrumental in enhancing the performance and longevity of critical medical devices.
“This acquisition represents an exciting new chapter for VSi Parylene,” stated Steve Neely, Co-Founder and CEO of VSi Parylene. “We have always been dedicated to providing our customers with the highest quality parylene coating services, and this strategic alignment will enable us to further expand our capabilities and reach. We are eager to leverage the resources and expertise of our new parent company to better serve the evolving needs of the medical device industry.”
VSi Parylene has built its reputation on its commitment to quality, precision, and customer satisfaction. The company’s advanced coating processes and rigorous quality control measures ensure that every parylene coated device or component meets the most stringent industry standards.
“Our focus remains on delivering innovative and reliable solutions that improve patient outcomes,” added Brian Behne, Co-Founder and COO of VSi Parylene. “We are confident that this acquisition will strengthen our ability to provide our customers with the cutting-edge parylene coating technologies they require.”
VSi Parylene will continue to operate with a focus on providing its customers with exceptional service and expertise. The company looks forward to leveraging its expanded resources to further enhance its product offerings and support the growth of its medical device partners.
About VSi Parylene
VSi Parylene is a leading provider of high-quality parylene coating services for the medical device industry. The company specializes in applying ultra-thin, biocompatible coatings that enhance the performance and longevity of critical medical devices. With a commitment to quality, precision, and customer satisfaction, VSi Parylene is a trusted partner for medical device manufacturers worldwide.
About Integer®
Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, the Company is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The Company’s brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net.
FAQs
What recent strategic move has VSi Parylene announced?
VSi Parylene has announced its acquisition by Integer Holdings Corporation, marking a significant milestone in its growth and reinforcing its commitment to delivering exceptional parylene coating solutions to its global clientele.
What is VSi Parylene known for in the medical device industry?
VSi Parylene is known for providing high-quality parylene coating services, specializing in applying ultra-thin, biocompatible coatings that enhance the performance and longevity of critical medical devices.
How will the acquisition by Integer Holdings Corporation benefit VSi Parylene?
The acquisition will enable VSi Parylene to expand its capabilities and reach by leveraging the resources and expertise of Integer Holdings Corporation, thereby better serving the evolving needs of the medical device industry.
What is Integer Holdings Corporation's role in the medical device industry?
Integer Holdings Corporation is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving various markets including cardiac rhythm management, neuromodulation, and cardio and vascular markets. They are committed to enhancing patient lives by providing innovative, high-quality products and solutions.
